|
|
|
|
|
|
|
|
|
|
|
20.11.26 - 16:45
|
Abivax-Aktie: Shortseller attackiert Pharmaunternehmen – was ist dran an den Vorwürfen? (Sharedeals)
|
|
|
Ein 297 Seiten langer Untersuchungsbericht löst einen massiven Kurssturz bei Abivax aus. Der Shortseller Scorpion Capital erhebt schwerwiegende Vorwürfe gegen den französischen Biotechkonzern: Der wichtigste Medikamentenkandidat Obefazimod könnte eine problematische chemische Struktur, erhebliche toxikologische Risiken und einen ganz anderen Wirkmechanismus haben als bislang kommuniziert. Auch die Aussagekraft der Phase-III-Studien wird angezweifelt. Die Konsequenzen könnten für […]
The post Abivax-Aktie: Shortseller attackiert Pharmaunternehmen – was ist dran an den Vorwürfen? first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.10.26 - 08:24
|
Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026 (Business Wire)
|
|
|
Operational launch of InVimmune, a subsidiary dedicated to differentiated approaches to in vivo cell therapy, with a first indication announced in oncology.
Appointment of Gilles Besin as Chief Executive Officer, effective July 2026.
Signing of a binding term sheet with Abivax with a view to an exclusive global collaboration.
Achievement of a major strategic milestone with the acquisition of Etherna Immunotherapies NV; the transaction is expected to be finalised on 8 October 2026.
Cash and cash equivalents totaling €656,000 as at 30 June 2026. As of the date of the half-year financier report, the cash position covers 12 months.
VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News:
Valerio Therapeutics (FR0010095596 - ALVIO), a pioneering biotechnology company in the field of next-generation precision therapies (“Valerio”, or the “Company”), provides an update on its operations and presents its financial results for the half-year ended 30 June 2026.
“The first half of 2026 marked a decisive mile...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|